Erratum: A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model (Diabetes and Vascular Disease Research (2011) 8:2 (117-124) DOI: 10.1177/1479164111404257);A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model

Diabetes and Vascular Disease Research

Volumn 8, Issue 2, 2011, Pages 117-124

  Gaspari, Tracey ^a   Liu, HongBin ^a,b   Welungoda, Iresha ^a   Hu, Yunshan ^a,b   Widdop, Robert E ^a   Knudsen, Lotte B ^c   Simpson, Richard W ^b,d   Dear, Anthony E ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c NOVO NORDISK A S   (Denmark)

^d BOX HILL HOSPITAL   (Australia)

Author keywords

Endothelium; GLP 1; Incretin; Liraglutide; NF B

Indexed keywords

APOENZYME; CELL ADHESION MOLECULE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LIRAGLUTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; VASCULAR ADHESION MOLECULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CELL ADHESION; CELL FUNCTION; CELL PROTECTION; DIABETES MELLITUS; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VASCULAR DISEASE; VASCULAR ENDOTHELIAL CELL;

EID: 79959237560     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111426971     Document Type: Erratum

References (29)

1. Hobb FD. Type-2 diabetes mellitus related cardiovascular risk: new options for interventions to reduce risk and treatment goals. Atherosclerosis 2006; 7: 29-32.
2. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.
3. Morigi M, Angioletti S, Imberti B, et al. Leukocyte - endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NFkB-dependent fashion. J Clin Invest 1998; 101: 1905-1915. (Pubitemid 28226110)
4. Liu HB, Hu YS, Medcalf RL, Simpson RW and Dear AE. Thiazolidinediones inhibit TNF alpha induction of PAI-1 independent of PPARgamma activation. Biochem Biophys Res Commun 2005; 334: 30-37. (Pubitemid 40978503)
5. Liu HB, Hu YS, Simpson RW and Dear AE. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen activator inhibitor-1 expression. J Endocrinol 2008; 196: 57-65. (Pubitemid 351234571)
6. Norata GD, Tibolla G, Seccomandi PM, Poletti A and Catapano AL. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 2006; 91: 546-554. (Pubitemid 43236925)
7. Kumar S, Sharma A, Madan B, Singhal V and Ghosh B. Isoliquiritigenin inhibits IkB kinase activity and ROS generation to block TNF-alpha induced expression of cell adhesion molecules on human endothelial cells. Biochem Pharmacol 2007; 73: 1602-1612. (Pubitemid 46533973)
8. Iwasaki H, Okamoto R, Kato S, et al High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 2008; 196: 22-28.
9. Kim W and Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
10. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010; 30: 609-624.
11. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon like peptide on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-E1215. (Pubitemid 39491964)
12. Golpon HA, Puechner A, Welte T, Wichert PV and Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102: 81-86.
13. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl saltsensitive rats. J Hypertens 2003; 21: 1125-1135. (Pubitemid 36667866)
14. Elbrønd B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398-1404. (Pubitemid 41071152)
15. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 424-429. (Pubitemid 34764798)
16. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194. (Pubitemid 38569002)
17. Vilsböll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care 2007; 30: 1608-1610. (Pubitemid 46871185)
18. Courrèges JP, Vilsbøll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25: 1129-1131.
19. Liu HB, Dear AE, Knudsen LB and Simpson RW. A longacting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009; 201: 59-66.
20. Cockerill GW, Meyer G, Noack L, Vadas MA and Gamble JR. Characterization of a spontaneously transformed human endothelial cell line. Lab Invest 1994; 71: 497-509. (Pubitemid 24338157)
21. Rolin B, Larsen MO, Gotfredsen CF, et al. The longacting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 83: E745-E752.
22. De León DD, Li C, Delson MI, Matschinsky FM, Stanley CA and Stoffers DA. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion. J Biol Chem 2008; 283: 25786-25793.
23. Vinh A, Widdop RE, Drummond GR and Gaspari TA. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 2008; 77: 178-187. (Pubitemid 351195149)
24. Blankenberg S, Barbaux S and Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203. (Pubitemid 37377790)
25. Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010; 53: 2256-2263.
26. Trottein F, Nutten S, Angeli V, et al. Schistosoma mansoni schistosomula reduce E-selectin and VCAM-1 expression in TNF-alpha-stimulated lung microvascular endothelial cells by interfering with the NF-kappaB pathway. Eur J Immunol 1999; 29: 3691-3701. (Pubitemid 29527818)
27. Kang JH, Chang SY, Jang HJ, et al. Exendin-4 inhibits interleukin-1beta-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F beta-cells. J Endocrinol 2009; 202: 65-75.
28. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030-1037.
29. Ten RM, Paya CV and Israël N. The characterization of the promoter of the gene encoding the p50 subunit of NF-kappa B indicates that it participates in its own regulation. EMBO J 1992; 11: 195-203.